Literature DB >> 16135087

Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease.

Bruce G Jenkins1, Ole A Andreassen, Alpaslan Dedeoglu, Blair Leavitt, Michael Hayden, David Borchelt, Christopher A Ross, Robert J Ferrante, M Flint Beal.   

Abstract

Huntington's disease is a neurodegenerative illness caused by expansion of CAG repeats at the N-terminal end of the protein huntingtin. We examined longitudinal changes in brain metabolite levels using in vivo magnetic resonance spectroscopy in five different mouse models. There was a large (>50%) exponential decrease in N-acetyl aspartate (NAA) with time in both striatum and cortex in mice with 150 CAG repeats (R6/2 strain). There was a linear decrease restricted to striatum in N171-82Q mice with 82 CAG repeats. Both the exponential and linear decreases of NAA were paralleled in time by decreases in neuronal area measured histologically. Yeast artificial chromosome transgenic mice with 72 CAG repeats, but low expression levels, had less striatal NAA loss than the N171-82Q mice (15% vs. 43%). We evaluated the effect of gene context in mice with an approximate 146 CAG repeat on the hypoxanthine phosphoribosyltransferase gene (HPRT). HPRT mice developed an obese phenotype in contrast to weight loss in the R6/2 and N171-82Q mice. These mice showed a small striatal NAA loss (21%), and a possible increase in brain lipids detectable by magnetic resonance (MR) spectroscopy and decreased brain water T1. Our results indicate profound metabolic defects that are strongly affected by CAG repeat length, as well as gene expression levels and protein context.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135087     DOI: 10.1111/j.1471-4159.2005.03411.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  28 in total

1.  Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.

Authors:  Lori Zacharoff; Ivan Tkac; Qingfeng Song; Chuanning Tang; Patrick J Bolan; Silvia Mangia; Pierre-Gilles Henry; Tongbin Li; Janet M Dubinsky
Journal:  J Cereb Blood Flow Metab       Date:  2011-11-02       Impact factor: 6.200

Review 2.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

3.  Comparison of analytical mathematical approaches for identifying key nuclear magnetic resonance spectroscopy biomarkers in the diagnosis and assessment of clinical change of diseases.

Authors:  Jason B Nikas; C Dirk Keene; Walter C Low
Journal:  J Comp Neurol       Date:  2010-10-15       Impact factor: 3.215

4.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

Review 5.  Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Nathanael Hevelone; Steven M Hersch
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

Review 6.  Huntington's disease: can mice lead the way to treatment?

Authors:  Zachary R Crook; David Housman
Journal:  Neuron       Date:  2011-02-10       Impact factor: 17.173

Review 7.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 8.  Mutant huntingtin and mitochondrial dysfunction.

Authors:  Ella Bossy-Wetzel; Alejandra Petrilli; Andrew B Knott
Journal:  Trends Neurosci       Date:  2008-10-24       Impact factor: 13.837

9.  Probing the metabolic aberrations underlying mutant huntingtin toxicity in yeast and assessing their degree of preservation in humans and mice.

Authors:  P Matthew Joyner; Ronni M Matheke; Lindsey M Smith; Robert H Cichewicz
Journal:  J Proteome Res       Date:  2010-01       Impact factor: 4.466

10.  Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation.

Authors:  Ji-Kyung Choi; Ekkehard Küstermann; Alpaslan Dedeoglu; Bruce G Jenkins
Journal:  Eur J Neurosci       Date:  2009-11-20       Impact factor: 3.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.